DNAPrint genomics Ticker Symbol Changing to 'DNAG' SARASOTA, Fla., July 11 /PRNewswire-FirstCall/ -- DNAPrint genomics, Inc. (OTC:DNAP) (BULLETIN BOARD: DNAP) today announced that commencing with the opening of the market on Tuesday, July 12, 2005, the Company's Common Stock will begin trading on the Over-the-Counter Bulletin Board under the symbol "DNAG." The change of the symbol is the result of a stock consolidation approved by shareholders and the Board of Directors that also becomes effective the same day. About DNAPrint genomics, Inc. DNAPrint genomics, Inc. ( http://www.dnaprint.com/ ) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. The Company's first theranostic product (drug/test combination) is PT- 401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre- clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response. Company Contact: Richard Gabriel CEO and President 941-366-3400 -or- Ron Stabiner The Wall Street Group, Inc. 212-888-4848 DATASOURCE: DNAPrint genomics CONTACT: Richard Gabriel, CEO and President, DNAPrint genomics, +1-941-366-3400; or Ron Stabiner, The Wall Street Group, Inc., +1-212-888-4848, for DNAPrint genomics Web site: http://www.dnaprint.com/

Copyright